Clinical experience with bemiparin

Area of Science:

• Pharmacology and Therapeutics
• Vascular Medicine
• Surgical Thromboprophylaxis

Background:

• Venous thromboembolism (VTE) poses a significant risk in moderate to high-risk surgical patients, with incidence rates of 15-60% without prophylaxis.
• Effective thromboprophylaxis can reduce VTE incidence by over 70%.

Purpose of the Study:

• To evaluate the efficacy and safety of subcutaneous bemiparin for VTE prevention and treatment in surgical patients.
• To compare bemiparin with unfractionated heparin (UFH), enoxaparin, and warfarin in various clinical scenarios.

Main Methods:

• Comparative studies evaluating bemiparin versus UFH, enoxaparin, and warfarin for VTE prophylaxis and treatment.
• Analysis of VTE incidence, bleeding episodes, and cost-effectiveness.

Main Results:

• Bemiparin demonstrated comparable efficacy to UFH and enoxaparin in VTE prevention, with significantly fewer bleeding episodes than UFH.
• Postoperative initiation of bemiparin was as effective as preoperative initiation but with lower bleeding risk.
• Bemiparin was more effective than IV UFH for acute DVT treatment and as effective as warfarin for secondary prevention.
• Extended prophylaxis (4 weeks) in cancer patients significantly reduced VTE rates without increasing bleeding.
• Outpatient treatment of acute VTE with bemiparin was effective and cost-saving compared to inpatient treatment.

Conclusions:

• Subcutaneous bemiparin is an effective and well-tolerated agent for VTE prophylaxis and treatment in surgical patients.
• Postoperative initiation of bemiparin offers advantages in terms of safety, cost-effectiveness, and reduced complications, particularly in patients with neuraxial anesthesia.
• Bemiparin presents a favorable profile compared to UFH and enoxaparin, with potential cost savings and improved quality of life.